Moderna stock falls after earnings as FDA decision approaches

Moderna stock falls after earnings as FDA decision approaches
Post-earnings volatility remains elevated.

​Moderna shares came under pressure following the company's quarterly earnings release, despite results that exceeded analysts' expectations.

Moderna reported a loss of $1.97 per share, compared with analysts' expectations for a loss of approximately $2.04 per share. Revenue totaled $145 million, comfortably beating the consensus estimate of $103.9 million. However, investors were disappointed by a 63% decline in revenue compared with the previous quarter.

At the same time, Moderna reaffirmed its 2026 revenue growth guidance of up to 10% and improved its operating expense outlook. Even so, investors remain focused on the pace of commercialization for the company's new products and its ability to offset declining COVID-19 vaccine sales across certain markets.

Gap down shifts focus to key support 

A gap down has formed in premarket trading, making long positions against the direction of the gap unattractive at this stage.

The key support level is located around $51.80. If sellers establish a sustained move below this level, the probability of a decline toward the 200-day SMA near $44.70 will increase.

Today's trading session is likely to remain highly volatile. If the stock manages to hold above $55, Moderna shares could attempt a recovery toward $60.

All eyes on the upcoming FDA decision 

Despite the negative post-earnings market reaction, Moderna may still have an opportunity to recover part of its recent losses. The next major catalyst will be the FDA's decision on the mRNA-1010 seasonal influenza vaccine, which is expected on August 5, 2026.

This material may contain third-party opinions, none of the data and information on this webpage constitutes investment advice according to our Disclaimer. While we adhere to strict Editorial Integrity, this post may contain references to products from our partners.